February 27 - 28, 2017
Keynote Speaker: James P. Allison (University of Texas MD Anderson Cancer Center)
Discover the latest on immunotherapeutic strategies that are currently being employed to treat some of the most devastating forms of cancer from leading experts in immunotherapy.
This event is sold out.
Wednesday, March 1, 2017 | 9:00 AM - 5:00 PM
Keynote Speaker: Harlan Robins (Fred Hutchinson Cancer Research Center)
This symposium will explore the emerging field of quantitative immuno-oncology, covering the breadth of scientific topics and methods needed to quantify interactions between tumors and the immune system.
Monday, March 13, 2017 | 9:00 AM - 5:00 PM
Speakers: Michael G. Agadjanyan (The Institute for Molecular Medicine), Bernardino Ghetti, (Indiana University School of Medicine), Andreas Muhs (AC Immune SA), Michal Novák (AXON Neuroscience SE), Einar M. Sigurdsson (NYU School of Medicine), Henrik Zetterberg (University of Gothenburg, Sweden), and Khalid Iqbal (New York State Institute for Basic Research)
This event will cover the translational potential of immunotherapy for tauopathies, reviewing the pre-clinical and clinical development of several tau immunotherapy programs that exemplify this emerging therapeutic approach.
March 15 - 16, 2017
Experience a public-facing dialogue exploring the nuanced ethical and scientific rationale behind randomized controlled clinical trials, accelerated alternatives, and the implications of these discussions on drug approval and patient interests.
Tuesday, March 21, 2017 | 12:00 PM - 5:00 PM
Speakers: Tsuneya Ikezu (Boston University School of Medicine), David Issadore (University of Pennsylvania), Xandra Breakefield (Massachusetts General Hospital), Efrat Levy (NYU School of Medicine), Robert A. Rissman (University of California San Diego, School of Medicine), and Andrew West (The University of Alabama at Birmingham)
In this symposium we will explore the contribution of extracellular vesicles to pathological processes underling neurodegenerative disorders, and the appeal of exosomes as biomarkers and targets for the development of novel therapeutics.
Tuesday, December 6, 2016 | 9:00 AM - 5:00 PM
Speakers: Katerina Akassoglou (University of California, San Francisco), Robert Dempsey (University of Wisconsin), Paula Grammas (University of Rhode Island), Steven Greenberg (Massachusetts General Hospital and Harvard Medical School), Jaime Grutzendler (Yale University), Costantino Iadecola (Weill Cornell Medicine), Jeffrey Iliff (Oregon Health & Science University), Berislav Zlokovic (Keck School of Medicine of USC), Heather Snyder (Alzheimer's Association), Zorina Galis (NIH)
This symposium will highlight basic research and clinical science elucidating the mechanisms underlying the contribution of inflammatory pathways to vascular cognitive impairment and dementia (VCID).
Tuesday, November 15, 2016 | 9:00 AM - 4:30 PM
Speakers: Thaddeus Stappenbeck (Washington University School of Medicine), Declan F. McCole (University of California Riverside), Jerrold R. Turner (Brigham and Women's Hospital), Linda G. Griffith (MIT), Tim Denning (Georgia State University), and Alan Hanash (Memorial Sloan Kettering Cancer Center)
This symposium will evaluate emerging research investigating the benefits of achieving mucosal healing in the treatment of intestinal disorders.
Thursday, November 10, 2016 | 8:00 AM - 6:00 PM
Keynote Speaker: Christopher E. Mason (Weill Cornell Medical College)
This conference will explore novel target and validation strategies, translational approaches to assess predictive and response biomarkers, resistance mechanisms, and combination strategies for targeting epigenetic susceptibilities in cancer.
Wednesday, November 9, 2016 | 8:30 AM - 5:15 PM
Keynote Speaker: Lawrence D. Mayer (Jazz Pharmaceuticals)
Explore approaches for complex drug development and regulation, outstanding challenges in the assessment of complex drug equivalence, consequences for product interchangeability, and compare biological and non-biological complex drug families.
Keynote Speakers: Barry G. Arnason, MD (University of Chicago) and Giancarlo Comi, MD (Università Vita-Salute San Raffaele)
This one-day, translational conference brought together academic and clinical researchers with industry leaders to discuss current therapeutics.
Keynote Speaker: David Bartel (Whitehead Institute for Biomedical Research, Howard Hughes Medical Institute, MIT)
MicroRNAs (miRNA) play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.
Featuring: Sharon Inouye (Harvard Medical School)
Surgery helps millions of Americans overcome illness to live longer, healthier lives. Yet surgery can lead to delirium, cognitive decline, and perhaps even a higher long-term risk of dementia for many patients, a risk that is poorly understood and often under-recognized in the clinic. With numerous factors—including age—contributing to each patient's level of risk, what are the challenges and opportunities to creating biomarkers and therapeutics for those who are most vulnerable?
Edited by Hui B. Sun
(Albert Einstein College of Medicine)
The papers in this Annals issue explore novel musculoskeletal repair and regeneration strategies that could be translated to clinical treatment of rotator cuff injuries, osteoarthritis, and other bone and cartilage diseases.